20. Paradigm shift from traditional to virtual. Stephen K. Durham, Lead Safety Assessment, Bristol-Myers Squibb, P.O. Box 4000, Princeton, NJ 08543, Fax: 609-252-7156, firstname.lastname@example.org
The intensely competitive global pharmaceutical business environment has forced the need for the early and successful selection of viable drug candidates, and the abandonment of the traditional development paradigm. The enormous drug developmental costs necessitate the identification of toxicologic liabilities of novel compounds during the initial and least expensive phase of the discovery process. The incorporation of in silico programs to predict toxicity, accompanied by aggressive model development, will be fruitful avenues worth pursuit in the drug candidate evaluation algorithm.